CLINICAL TRIALS PROFILE FOR RUXIENCE

Biosimilar Clinical Trials for RUXIENCE

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04555811 ↗	FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL	Recruiting	Masonic Cancer Center, University of Minnesota	Phase 1	2020-09-22	This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.

All Clinical Trials for RUXIENCE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04189588 ↗	Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine	Completed	TerSera Therapeutics	Phase 2	2020-03-25	This study is designed to compare the incidence of infusion reactions to treatment with an anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel after 6 months or in patients with persistent infusion reactions while on maintenance or retreatment.
NCT04189588 ↗	Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine	Completed	JDP Therapeutics, Inc.	Phase 2	2020-03-25	This study is designed to compare the incidence of infusion reactions to treatment with an anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel after 6 months or in patients with persistent infusion reactions while on maintenance or retreatment.
NCT04189588 ↗	Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine	Completed	TerSera Therapeutics LLC	Phase 2	2020-03-25	This study is designed to compare the incidence of infusion reactions to treatment with an anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel after 6 months or in patients with persistent infusion reactions while on maintenance or retreatment.

Clinical Trial Conditions for RUXIENCE

Condition Name

Condition Name for RUXIENCE
Intervention	Trials
Chronic Lymphocytic Leukemia	3
Small Lymphocytic Lymphoma	2
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements	1

Condition MeSH

Condition MeSH for RUXIENCE
Intervention	Trials
Lymphoma	5
Leukemia	5
Leukemia, Lymphoid	4

Clinical Trial Locations for RUXIENCE

Trials by Country

Trials by Country for RUXIENCE
Location	Trials
United States	18
Belgium	5
Japan	2
Denmark	2
Netherlands	1

Trials by US State

Trials by US State for RUXIENCE
Location	Trials
California	3
New York	2
Missouri	2
Minnesota	2
Texas	2

Clinical Trial Progress for RUXIENCE

Clinical Trial Phase

Clinical Trial Phase for RUXIENCE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	6
Phase 2	3

Clinical Trial Status

Clinical Trial Status for RUXIENCE
Clinical Trial Phase	Trials
Recruiting	8
Not yet recruiting	4
Completed	1

Clinical Trial Sponsors for RUXIENCE

Sponsor Name

Sponsor Name for RUXIENCE
Sponsor	Trials
Loxo Oncology, Inc.	2
Odense University Hospital	1
Merck Sharp & Dohme LLC	1

Sponsor Type

Sponsor Type for RUXIENCE
Sponsor	Trials
Other	28
Industry	8
NIH	1